Enanta price target raised to $23 from $21 at Citizens JMP

Citizens JMP raised the firm’s price target on Enanta (ENTA) to $23 from $21 and keeps an Outperform rating on the shares. Enanta ended Q2 with cash of $193M and guiding to runway at least into fiscal 2028, and continues to advance its immunology pipeline, with the oral KIT and STAT6 candidates displaying good drug-like properties, the analyst tells investors in a research note.